Table 3.
Response to adavosertib treatment (part B expansion cohort)
| Parameter | Patient cohort | ||||||
|---|---|---|---|---|---|---|---|
| Ovarian cancer, BRCAwt | Ovarian cancer, BRCAm, PARPi failure | TNBC, CCNE1/MYC/ MYCL1/MYCN non-amplified | TNBC, CCNE1/MYC/ MYCL1/MYCN amplified | SCLC, CCNE1/MYC/ MYCL1/MYCN non-amplified | SCLC, CCNE1/MYC/ MYCL1/MYCN amplified | Total | |
| Patients who received treatment, n | 16 | 30 | 13 | 6 | 12 | 3 | 80 |
| ORR, n (%) | 1 (6.3) | 1 (3.3) | 0 | 0 | 1 (8.3) | 0 | 3 (3.8) |
| CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR | 1 (6.3) | 1 (3.3) | 0 | 0 | 1 (8.3) | 0 | 3 (3.8) |
| SDa | |||||||
| ≥ 5 weeks | 10 (62.5) | 22 (73.3) | 9 (69.2) | 3 (50.0) | 3 (25.0) | 1 (33.3) | 48 (60.0) |
| 12 weeksb | 8 (50.0) | 13 (43.3) | 5 (38.5) | 1 (16.7) | 2 (16.7) | 1 (33.3) | 30 (37.5) |
| Progressive disease | 4 (25.0) | 5 (16.7) | 3 (23.1) | 3 (50.0) | 7 (58.3) | 2 (66.7) | 24 (30.0) |
| Not evaluable | 1 (6.3) | 2 (6.7) | 1 (7.7) | 0 | 1 (8.3) | 0 | 5 (6.3) |
| Total evaluable | 14 (87.5) | 21 (70.0) | 9 (69.2) | 4 (66.7) | 11 (91.7) | 3 (100) | 62 (77.5) |
| DCR,c n (%) | 11 (68.8) | 23 (76.7) | 9 (69.2) | 3 (50.0) | 4 (33.3) | 1 (33.3) | 51 (63.8) |
| Median PFS, months | 4.5 | 3.9 | 3.1 | 2.0 | 1.3 | 1.2 | 3.0 |
BOR best objective response, BRCAm breast cancer gene 1/2 mutation, BRCAwt breast cancer gene 1/2 wild type, CCNE1 cyclin E1, CR complete response, DCR disease control rate, n number of patients, ORR objective response rate, PARPi poly(ADP-ribose) polymerase inhibitor, PFS progression-free survival, PR partial response, SCLC small-cell lung cancer, SD stable disease, TNBC triple-negative breast cancer
aSD indicates patients with a BOR of SD
bSD 12 weeks defined as BOR of SD for at least two post-baseline assessments
cDCR defined as the proportion of patients with a confirmed BOR of CR or PR, or BOR of SD